TRACK RECORD

From an innovative healthcare platform to independent growth

SIGMOLECS® represents one of the most significant projects developed within Contrad and illustrates the company’s project-development model in practice.

Starting from an innovative signalling-molecule technology, Contrad developed the platform into a portfolio of products for musculoskeletal and dermo-aesthetic applications. The project combined scientific and product development with clinical validation, regulatory planning, manufacturing, brand creation and international commercialization.

Having reached a new stage of maturity, the platform is now led independently through a dedicated structure focused on the next phase of its scientific, commercial and international development.

This evolution reflects Contrad’s approach: identifying differentiated healthcare opportunities, building their scientific and commercial value, and creating the appropriate conditions for their continued development and growth.

For current information about SIGMOLECS® and the associated product portfolio, visit Valtum SA.